| Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||||
Net loss | ||||||||
-37,066 | -31,506 | -20,163 | -11,094 | -14,083 | -13,628 | -12,004 | -7,203 | -3,831 |
Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
Gain from discontinued operations | ||||||||
- | - | - | - | - | - | - | - | 12 |
Stock-based compensation | ||||||||
2,633 | 3,084 | 3,773 | 3,633 | 3,543 | 2,469 | 3,400 | 2,337 | 1,529 |
Depreciation | ||||||||
1,593 | 1,484 | 1,106 | 658 | 370 | 299 | 179 | 201 | 264 |
Increase in severance pay, net | ||||||||
-33 | 101 | 120 | -55 | 59 | 75 | -7 | 92 | -117 |
Gain from sale of marketable securities | ||||||||
0 | 383 | 436 | 2,345 | 3,711 | - | - | - | - |
Loss from property and equipment disposal | ||||||||
0 | 0 | -37 | 0 | 0 | - | - | 25 | 102 |
Change in fair value of exchange option and embedded derivatives within research and development funding arrangement | ||||||||
- | - | - | 269 | -811 | -588 | -113 | -97 | 0 |
Gain from sale of marketable securities | ||||||||
- | - | - | - | - | 0 | 239 | 419 | 3,721 |
Amortization of the Research and Development Component within research and development funding arrangement | ||||||||
0 | 0 | 421 | 337 | 230 | 130 | 0 | 0 | - |
Change in the fair value of liability with respect to outstanding options to non-employee | ||||||||
- | - | - | - | -104 | -20 | 0 | 0 | - |
Loss in respect to Termination and Equity Conversion Agreement | ||||||||
- | - | - | -792 | 0 | 0 | - | - | - |
Decrease (increase) in interest receivables from short-term bank deposits | ||||||||
-247 | -303 | 399 | 142 | 0 | - | - | - | - |
Decrease (increase) in trade receivable | ||||||||
0 | -7,800 | 7,800 | 0 | 0 | - | - | - | - |
Decrease (increase) in other accounts receivable and prepaid expenses | ||||||||
-422 | -206 | 777 | -1,168 | 1,105 | 112 | -43 | -192 | -58 |
Decrease (increase) in long-term prepaid expenses | ||||||||
18 | -9 | -7 | -152 | -202 | 301 | 0 | 0 | - |
Increase in trade payables and other accounts payable and accrued expenses | ||||||||
1,564 | -605 | 823 | 1,674 | 1,037 | -86 | -734 | 562 | -1,534 |
Decrease in deferred revenues | ||||||||
0 | -312 | -1,477 | -4,983 | 6,772 | 0 | 0 | -113 | 13 |
Net cash used in operating activities | ||||||||
- | - | - | -11,148 | - | - | - | - | - |
Net cash used in operating activities | ||||||||
-30,658 | -19,819 | -25,607 | - | -6,439 | -10,846 | -9,249 | -4,279 | -7,453 |
Cash flows from investing activities: | ||||||||
Proceeds from maturity of short-term bank deposits | ||||||||
71,560 | 69,000 | 47,000 | 18,015 | 3,215 | 16,525 | 14,524 | 500 | 2,612 |
Investment in short-term and long-term bank deposits | ||||||||
24,900 | 50,561 | 34,000 | 82,026 | 18,015 | - | - | - | - |
Investment in short-term bank deposits | ||||||||
- | - | - | - | - | 3,215 | 16,525 | 14,524 | 500 |
Investment in long-term bank deposits | ||||||||
- | - | - | - | - | 0 | - | - | - |
Changes in restricted cash | ||||||||
- | - | - | 389 | 50 | 0 | -592 | 1 | 96 |
Purchase of property and equipment | ||||||||
385 | 2,599 | 3,120 | 1,896 | 328 | 1,005 | 96 | 46 | 48 |
Increase in long-term lease deposits | ||||||||
- | - | - | 102 | 0 | 42 | -47 | 46 | -23 |
Proceeds from sale of marketable securities | ||||||||
0 | 369 | 423 | 2,309 | 3,603 | - | - | - | - |
Net cash provided by investing activities | ||||||||
- | - | - | -64,089 | - | - | - | - | - |
Proceeds from sale of investment in Evogene | ||||||||
- | - | - | - | - | 0 | 232 | 424 | 3,557 |
Proceeds from sales of property and equipment | ||||||||
- | - | - | - | - | - | - | 25 | 185 |
Net cash provided by (used in) investing activities | ||||||||
46,275 | 16,209 | 10,303 | - | -11,575 | 12,263 | -1,226 | -13,668 | 5,733 |
Cash flows from financing activities: | ||||||||
Warrants issuance expenses in connection with funding arrangement | ||||||||
- | - | - | - | - | - | - | 61 | 0 |
Proceeds from issuance of ordinary shares and warrants, net | ||||||||
- | - | - | 70,718 | 19,760 | 6,211 | 0 | 7,790 | 12,013 |
Proceeds from research and development funding arrangements | ||||||||
- | - | - | - | 5,000 | 1,000 | 7,000 | - | 0 |
Proceeds from exercise of options | ||||||||
201 | 2,458 | 972 | 1,411 | 5,631 | 1,900 | 2,021 | 2,379 | 196 |
Net cash provided by financing activities | ||||||||
- | - | - | 72,129 | - | - | - | - | - |
Net cash provided by financing activities | ||||||||
201 | 2,458 | 972 | - | 30,391 | 9,111 | 9,021 | 10,108 | 12,209 |
Increase (decrease) in cash, cash equivalents and restricted cash | ||||||||
15,818 | -1,152 | -14,332 | -3,108 | 12,377 | 10,528 | -1,454 | -7,839 | 10,489 |
Supplemental disclosure of non-cash investing and financing activities: | ||||||||
Issuance of shares in respect to Termination and Equity Conversion Agreement | ||||||||
- | - | - | - | 0 | 0 | - | - | - |
Changes in receivables from foreign currency derivative contracts | ||||||||
-10 | 7 | -141 | 141 | 0 | 0 | - | - | - |
Changes in other accounts payable from foreign currency derivative contracts | ||||||||
0 | 19 | -19 | 0 | 0 | - | - | - | - |
Receivables from funding arrangement | ||||||||
- | - | - | - | - | - | - | 5,000 | - |
Receivables on account of shares | ||||||||
- | - | - | - | - | 56 | 20 | 0 | - |
Receivables on account of shares and from funding arrangement | ||||||||
- | - | - | - | - | - | - | - | 7,790 |
Receivables for other finance proceeds | ||||||||
- | - | - | - | - | - | - | 41 | 0 |
Purchase of property and equipment | ||||||||
33 | 143 | 1,321 | 284 | 0 | 47 | 0 | 0 | - |
Income taxes | ||||||||
0 | 20 | 0 | 360 | 500 | 0 | 0 | - | - |
Interest payments received from bank short-term deposits and cash equivalents | ||||||||
640 | -1,032 | -415 | - | - | - | - | - | - |
Interest payments received from bank short-term deposits and cash equivalents | ||||||||
- | - | - | 235 | -112 | -297 | -351 | - | - |
Proceeds from issuance of ordinary shares and warrants, net | ||||||||
- | - | - | 12,162 | - | - | - | - | - |